BIIB · Biogen Inc. · Documents

Apr 28

Proxy statement DEFA14A

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders

Apr 25

Earnings call

Q1 2023 earnings call

Apr 25

Current report 8-K

Financial results

Apr 25

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $2.46B ▼ 2.7% Net income $387.9M ▲ 27.7% Diluted EPS $2.67 ▲ 29.6%

Apr 18

Current report 8-K Events of Apr 12

Charter or bylaw amendment, or fiscal year change

Mar 9

Current report 8-K Events of Mar 5

Director or officer change, or executive pay, Other events

Feb 15

Earnings call

Q4 2022 earnings call

Feb 15

Current report 8-K

Financial results

Feb 15

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $10.17B ▼ 7.4% Net income $3.05B ▲ 95.8% Diluted EPS $20.87 ▲ 100.7%

Nov 10

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Oct 25

Earnings call

Q3 2022 earnings call

Oct 25

Current report 8-K

Financial results

Oct 25

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $2.51B ▼ 9.7% Net income $1.13B ▲ 244.7% Diluted EPS $7.84 ▲ 253.2%

Jul 20

Earnings call

Q2 2022 earnings call

Jul 20

Current report 8-K/A

Financial results

Jul 20

Current report 8-K

Financial results

Jul 20

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $2.59B ▼ 6.7% Net income $1.06B ▲ 135.9% Diluted EPS $7.24 ▲ 142.1%

Jun 21

Current report 8-K Events of Jun 15

Director or officer change, or executive pay, Shareholder vote results

Jun 7

Proxy statement DEFA14A

Proxy statement

May 17

Registration statement S-4

Registration statement

May 3

Earnings call

Q1 2022 earnings call

May 3

Current report 8-K

Financial results, Director or officer change, or executive pay

May 3

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $2.53B ▼ 6.0% Net income $303.8M ▼ 25.9% Diluted EPS $2.06 ▼ 23.4%

Apr 29

Proxy statement DEF 14A Meeting Jun 15, 2022

Proxy statement

Apr 29

Proxy statement DEFA14A

Proxy statement

Feb 3

Earnings call

Q4 2021 earnings call

Feb 3

Current report 8-K

Financial results

Feb 3

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $10.98B ▼ 18.3% Net income $1.56B ▼ 61.1% Diluted EPS $10.40 ▼ 58.1%

Jan 31

Current report 8-K Events of Jan 25

Director or officer change, or executive pay

Nov 19

Current report 8-K Events of Nov 18

Other events

Nov 17

Current report 8-K Events of Nov 15

Director or officer change, or executive pay

Oct 20

Earnings call

Q3 2021 earnings call

Oct 20

Current report 8-K

Financial results

Oct 20

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $2.78B ▼ 17.7% Net income $329.2M ▼ 53.1% Diluted EPS $2.22 ▼ 50.2%

Jul 22

Earnings call

Q2 2021 earnings call

Jul 22

Current report 8-K

Financial results

Jul 22

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $2.78B ▼ 24.6% Net income $448.5M ▼ 70.9% Diluted EPS $2.99 ▼ 68.8%

Jun 8

Current report 8-K Events of Jun 2

Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Apr 23

Proxy statement DEF 14A Meeting Jun 2, 2021

Proxy statement

Apr 23

Proxy statement DEFA14A

Proxy statement

Apr 22

Earnings call

Q1 2021 earnings call

Apr 22

Current report 8-K

Financial results

Apr 22

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $2.69B ▼ 23.8% Net income $410.2M ▼ 70.7% Diluted EPS $2.69 ▼ 66.7%

Apr 9

Current report 8-K Events of Apr 7

Director or officer change, or executive pay, Other events

Apr 9

Proxy statement PRE 14A Meeting Jun 2, 2021

Proxy statement

Apr 9

Proxy statement DEFA14A

Proxy statement

Feb 16

Current report 8-K

Other events

Feb 4

Current report 8-K

Other events

Feb 3

Earnings call

Q4 2020 earnings call